A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Study Summary

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Conditions

Cutaneous Melanoma Non-small Cell Lung Cancer Colorectal Neoplasms Pancreatic Neoplasms Mesothelioma

Interventions / Drugs

PF-08046049

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment41 participants

Primary Completion—

Lead SponsorSeagen, a wholly owned subsidiary of Pfizer

Data Retrieved2026-04-11 02:55:53.191235+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.